March 13, 2012British Journal of Dermatology

Successful treatment of moderate to severe plaque psoriasis with the PEGylated Fab′ certolizumab pegol: results of a phase II randomized, placebo-controlled trial with a re-treatment extension

View Full Paper

Ask AI

Bookmark

Abstract

Treatment with CZP significantly improved psoriasis at week 12. Similar efficacy was observed at week 12 in patients receiving re-treatment for loss of response after drug withdrawal.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Reich et al. (2012) studied this question.

synapsesocial.com/papers/69dbc31d3d9adb00e7684edc https://doi.org/10.1111/j.1365-2133.2012.10941.x

View Full Paper

Ask AI

Bookmark

Abstract

Treatment with CZP significantly improved psoriasis at week 12. Similar efficacy was observed at week 12 in patients receiving re-treatment for loss of response after drug withdrawal.

Successful treatment of moderate to severe plaque psoriasis with the PEGylated Fab′ certolizumab pegol: results of a phase II randomized, placebo-controlled trial with a re-treatment extension

Abstract

Discussion

Cite This Study

Successful treatment of moderate to severe plaque psoriasis with the PEGylated Fab′ certolizumab pegol: results of a phase II randomized, placebo-controlled trial with a re-treatment extension

Abstract

Discussion

Cite This Study

Keep reading

Keep reading